EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Procaps Group's enterprise value is $557.4 Mil.
Procaps Group's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $123.4 Mil. Therefore, Procaps Group's EV-to-EBITDA for today is 4.52.
The historical rank and industry rank for Procaps Group's EV-to-EBITDA or its related term are showing as below:
PROC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.97 Med: 8.24 Max: 123.51
Current: 4.52
During the past 4 years, the highest EV-to-EBITDA of Procaps Group was 123.51. The lowest was 3.97. And the median was 8.24.
PROC's EV-to-EBITDA is ranked better than 88.59% of 710
companies
in the Drug Manufacturers industry
Industry Median: 14.355
vs PROC: 4.52
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Procaps Group EV-to-EBITDA Historical Data
The historical data trend for Procaps Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Procaps Group's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Procaps Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procaps Group's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procaps Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Procaps Group's EV-to-EBITDA falls into.
Procaps Group EV-to-EBITDA Calculation
Procaps Group's EV-to-EBITDA for today is calculated as:
Procaps Group's current Enterprise Value is $557.4 Mil.
Procaps Group's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $123.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procaps Group (NAS:PROC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Procaps Group's PE Ratio for today is calculated as:
Procaps Group's share price for today is $2.60.
Procaps Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.520.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Procaps Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Procaps Group (Procaps Group) Business Description
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PROC has been successfully added to your 